AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 162 min read$CLOV

Wai Conrad sold $113K of CLOV

Wai Conrad (CEO, Counterpart Health) sold 24,215 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.67 ($0.11M total) on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Wai Conrad
Published Jul 16, 2026, 8:55 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 16, 2026, 9:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$CLOV
Neutral
high confidence
Mentioned
$CLOV
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVNeutralLow
01

Why it matters

The disclosure provides a concrete datapoint on CEO selling activity (shares, price, and post-transaction holdings) but does not introduce new operational or financial information.

02

Market read

Useful for monitoring insider behavior, but unlikely to drive a durable repricing without accompanying fundamental news.

03

What to watch

Traders may over-weight insider sales; the filing does not disclose changes to guidance, contracts, or regulatory/clinical developments.

Relevance 3/10Novelty 3/10Timing: new Form 4 filed 2026-07-16, covering a sale dated 2026-07-15

Background

The article is a SEC Form 4 insider transaction disclosure for Clover Health Investments, Corp. /DE.

Company-level read

Ticker impact

$CLOVNeutralHigh confidence
Context

Clover Health CEO Wai Conrad sold 24,215 shares at $4.6700 on 2026-07-15 under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited, with any impact confined to short-term sentiment rather than fundamentals.

Evidence & confidence

The filing is a routine Form 4 transaction with disclosed trade size, price, and 10b5-1 pre-arrangement, providing no new company-specific operating or financial information.

Market effects

Sector

Minimal, as this is company-specific insider selling with no sector-wide signal.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale was executed under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • issuer
    CLOV

    Clover Health Investments, Corp. /DE, the company whose CEO insider sale is disclosed.

  • insider
    Wai Conrad

    CEO, Counterpart Health, who sold 24,215 shares under a 10b5-1 plan.

Read at source← All news

Related articles

AUG 7
$CLOVMedAI 8/10

Clover Health Investments Q2 Earnings Call Highlights

Clover Health Investments (CLOV) reported Q2 adjusted EBITDA of $41 million and GAAP net income of $28 million. For the first half of 2026, it posted $81 million adjusted EBITDA and $55 million GAAP net income, with $443 million cash and investments and no debt. The company raised 2026 guidance to $2.92B-$3.0B revenue and $70M-$85M adjusted EBITDA, and discussed cohort maturation and 4.5-star ratings for 2027.

yahoo.com6 min
AUG 6
$METMed

Financial results round-up: MetLife, Prudential, Corebridge, Palomar, Heritage, TWFG, Root and more

A financial results roundup covers multiple insurers and MGAs. MetLife reported Q2 net income of $705m and adjusted EPS $2.43. Prudential posted Q2 net income of $985m and record individual life sales. Corebridge reported a $16m net loss and merger approval. Palomar, Heritage, TWFG, Root, Trupanion and Clover Health also reported Q2 figures and guidance updates.

insurancebusinessmag.com9 min
AUG 5
$CLOVHighAI 9/10

CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV): Results of Operations and Financial Condition

CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2q26exx991xearningsrelease.htm EX-99.1 Document Exhibit 99.1 Clover Health Reports Second Quarter 2026 Results Business Highlights: • Delivered strong second quarter 2026 GAAP Net Income alongside continued market-leading Medicare Advantage membership growth • Improved

SEC EDGAR 8-K6 min
JUL 24
$CLOVMed

What's Fueling Clover Health's Recent Stock Surge

Clover Health (CLOV) shares rose about 7% to $2.39 after UnitedHealth Group (UNH) reported strong Q1 2026 results and raised its full-year adjusted net earnings outlook to over $18.25 per share, lifting sentiment for health insurers. Clover also cited 53% YoY Medicare Advantage membership growth and reiterated 2026 GAAP net income profitability guidance. Analysts maintain a Hold rating and a $2.90 average target.

kavout.com4 min